SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca). The study results were presented at the Dry Eye Summit meeting on April 30th in Fort Lauderdale, Florida, immediately prior to ARVO 2010, the annual meeting of the Association for Research in Vision and Ophthalmology. The study results demonstrated clear improvements in both signs and symptoms of dry eye at 12 weeks. SAR 1118 was well-tolerated, with no serious ocular adverse events reported.
"We are very pleased with the results of the Phase 2 study," said Charles Semba, MD, chief medical officer of SARcode. "We met our goals of showing improvements in both corneal staining and patient symptoms. We were encouraged too that SAR 1118 achieved these results within 12 weeks, suggesting that it might provide more rapid relief than currently available therapies."
Study reveals how brainstem neurons control eye movements